Ticlopidine (HCl)
Ticlopidine (HCl) reduces platelet aggregation. Ticlopidine (HCl) acts by producing changes (may be irreversible) to the platelet membrane reducing their ability to form blood clots with fibrin. itused in combination with other antiplatelet drugs to reduce the risk of further thrombolytic events. itperticularly useful in patients who cannot tolerate aspirin.
Primary Characteristics
It belongs to Pyridine.
Molecular Weight: 300.2 · Solubility in Water: sparingly soluble · Solubility in Alcohol: sparingly soluble · Non-proprietary name: Ticlopidine (HCl).
Pharmacokinetics
Distribution: Ticlopidine (HCl) has a plasma protein binding is 98 %.
Elimination: plasma half-life is 12.6 hr, renal excretion is 60 %.
Advertisement
Indications
Ticlopidine (HCl) is primarily indicated in conditions like Cardiac stroke, Ischaemic heart disease, Thromboembolism.
Contraindications
Ticlopidine (HCl) is contraindicated in conditions like Thrombocytopenia, GI ulceration, Leukopenia, Agranulocytosis, Hemorrhagic diathesis.
Dosage
Ticlopidine (HCl)'s dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 250 mg | 250 mg | Every 12h | PO | With meals. |
| Paediatric Dosage (20kg) | ||||
| 0 – 0 | — | — | Not recommended in this age group | |
| Neonatal Dosage (3kg) | ||||
| 0 – 0 | — | — | Not recommended in this age group | |
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Ticlopidine (HCl) in overdosage may give rise to further complications which include Aplastic anemia , Hepatic necrosis , Jaundice , Peptic ulceration , Renal failure , Stevens johnson syndrome .
Ticlopidine (HCl) is known to cause more or less tolerable side effects which are usually transient. These include Anorexia , Dizziness, Flatulence, GI hemorrhage, Headache, Hematuria, Increased intracranial pressure, Menorrhagia , Neutropenia, Pain , Pancytopenia , Pruritus , Rashes , Thrombocytopenia, Vomiting , Weakness.
Warnings / Precautions
Interference in Pathology
Ticlopidine (HCl) may interfere in the diagnosis of Interferes with LFT .
Available Brands
Click on a strength to view available brands.
Single Ingredient
Storage Conditions
Drug Classification
- 1.10.2 — Anticoagulants/Platelet deaggregators